Spirocyclic compounds as tryptophan hydroxylase inhibitors
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
1. A method of treating a patient, comprising administering to the patient a therapeutically effective amount of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, wherein the patient has been diagnosed with a bone disease or a cardiovascular disease.
2. The method of claim 1 , wherein administration is by inhalation.
3. The method of claim 2 , wherein inhalation is with a powder.
4. The method of claim 2 , wherein inhalation is with a spray or an aerosol.
5. The method of claim 4 , wherein inhalation is via a sonic nebulizer.
6. The method of claim 1 , wherein administration is by injection.
7. The method of claim 6 , wherein injection is subcutaneous, intravenous, or intramuscular.
8. The method of claim 1 , wherein administration is by infusion.
9. The method of claim 1 , wherein administration is oral.
10. A method of lowering peripheral serotonin in a patient comprising administering a therapeutically effective amount of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, wherein the patent has been diagnosed with a disease associated with abnormal expression or activity of tryptophan hydroxylase isoform 1 (TPH1 enzyme) or a disease associated with elevated or abnormal peripheral serotonin levels.
11. The method of claim 10 , wherein administration is by inhalation.
12. The method of claim 11 , wherein inhalation is with a powder.
13. The method of claim 11 , wherein inhalation is with a spray or an aerosol.
14. The method of claim 13 , wherein inhalation is via a sonic nebulizer.
15. The method of claim 10 , wherein administration is by injection.
16. The method of claim 15 , wherein injection is subcutaneous, intravenous, or intramuscular.
17. The method of claim 10 , wherein injection is subcutaneous, intravenous, or intramuscular.
18. The method of claim 10 , wherein administration is oral.
19. The method of claim 1 , wherein the effective amount inhibits the activity of the TPH1 enzyme.
20. The method of claim 1 , wherein (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof has a selectivity for peripheral serotonin over non-peripheral serotonin by 2-fold or more.
21. The method of claim 1 , wherein the patient has a bone disease selected from the group consisting of osteoporosis, osteoporosis pseudoglioma syndrome, osteopenia, osteomalacia, renal osteodystrophy, Paget's disease, fractures, and bone metastasis.
22. The method of claim 1 , wherein the patient has atherosclerosis or pulmonary hypertension.
23. The method of claim 10 , wherein the patient has a bone disease selected from the group consisting of osteoporosis, osteoporosis pseudoglioma syndrome, osteopenia, osteomalacia, renal osteodystrophy, Paget's disease, fractures, and bone metastasis.
24. The method of claim 10 , wherein the patient has atherosclerosis or pulmonary hypertension.